Last reviewed · How we verify
Simvastatin 80mg
Simvastatin 80mg, marketed by Helsinki University Central Hospital, is a well-established lipid-lowering therapy. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market position. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | Simvastatin 80mg |
|---|---|
| Also known as | simvastatin, Zocor |
| Sponsor | Helsinki University Central Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC (PHASE1)
- Simvastatin in Secondary Progressive Multiple Sclerosis (PHASE2)
- Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer (PHASE2)
- Multiple Sclerosis-Simvastatin Trial 2 (PHASE3)
- Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122) (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PHASE4)
- Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Simvastatin 80mg CI brief — competitive landscape report
- Simvastatin 80mg updates RSS · CI watch RSS
- Helsinki University Central Hospital portfolio CI